Concepts (278)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medication Adherence | 31 | 2025 | 391 | 10.320 |
Why?
|
| Medicare Part C | 11 | 2024 | 35 | 5.600 |
Why?
|
| Motivational Interviewing | 7 | 2023 | 46 | 4.840 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2025 | 720 | 4.430 |
Why?
|
| Hypertension | 13 | 2025 | 1286 | 3.920 |
Why?
|
| Hyperlipidemias | 6 | 2025 | 175 | 3.560 |
Why?
|
| Diabetes Mellitus | 10 | 2025 | 853 | 2.770 |
Why?
|
| Smoking Cessation | 7 | 2016 | 197 | 2.720 |
Why?
|
| Antihypertensive Agents | 6 | 2025 | 397 | 2.680 |
Why?
|
| Atrial Fibrillation | 5 | 2024 | 633 | 2.250 |
Why?
|
| Smoking | 8 | 2016 | 1034 | 1.880 |
Why?
|
| Anticoagulants | 4 | 2024 | 581 | 1.850 |
Why?
|
| Hypoglycemic Agents | 4 | 2025 | 436 | 1.760 |
Why?
|
| United States | 39 | 2025 | 10739 | 1.700 |
Why?
|
| Aged | 43 | 2025 | 19349 | 1.630 |
Why?
|
| Medicare | 14 | 2024 | 422 | 1.610 |
Why?
|
| Drug Therapy, Combination | 6 | 2025 | 1153 | 1.460 |
Why?
|
| Retrospective Studies | 44 | 2025 | 16195 | 1.460 |
Why?
|
| Medicare Part D | 2 | 2021 | 17 | 1.430 |
Why?
|
| Cardiovascular Diseases | 7 | 2025 | 1886 | 1.300 |
Why?
|
| Pharmaceutical Services | 3 | 2021 | 35 | 1.240 |
Why?
|
| Angiotensin Receptor Antagonists | 7 | 2025 | 122 | 1.210 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 7 | 2025 | 211 | 1.170 |
Why?
|
| Rivaroxaban | 2 | 2024 | 55 | 1.120 |
Why?
|
| Factor Xa Inhibitors | 2 | 2024 | 64 | 1.100 |
Why?
|
| Pyridones | 2 | 2024 | 112 | 1.080 |
Why?
|
| Markov Chains | 2 | 2024 | 83 | 1.080 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2024 | 106 | 1.070 |
Why?
|
| Varenicline | 2 | 2016 | 14 | 1.030 |
Why?
|
| Bupropion | 2 | 2016 | 27 | 1.020 |
Why?
|
| Antipsychotic Agents | 6 | 2024 | 373 | 1.020 |
Why?
|
| Stroke | 2 | 2024 | 970 | 0.990 |
Why?
|
| Pyrazoles | 2 | 2024 | 305 | 0.960 |
Why?
|
| Administration, Oral | 6 | 2025 | 675 | 0.950 |
Why?
|
| Aged, 80 and over | 15 | 2025 | 6434 | 0.950 |
Why?
|
| Breast Neoplasms | 10 | 2023 | 2489 | 0.930 |
Why?
|
| Humans | 79 | 2025 | 124083 | 0.920 |
Why?
|
| Cost-Benefit Analysis | 2 | 2024 | 505 | 0.920 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2024 | 1241 | 0.920 |
Why?
|
| Monte Carlo Method | 1 | 2024 | 92 | 0.910 |
Why?
|
| Administrative Claims, Healthcare | 2 | 2021 | 15 | 0.910 |
Why?
|
| Texas | 15 | 2025 | 3586 | 0.900 |
Why?
|
| Obesity | 6 | 2023 | 2249 | 0.850 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2019 | 722 | 0.850 |
Why?
|
| Female | 55 | 2025 | 66156 | 0.820 |
Why?
|
| Warfarin | 2 | 2022 | 118 | 0.780 |
Why?
|
| Male | 46 | 2025 | 60804 | 0.770 |
Why?
|
| Students | 3 | 2013 | 255 | 0.770 |
Why?
|
| Logistic Models | 11 | 2021 | 1805 | 0.740 |
Why?
|
| Hemorrhage | 1 | 2024 | 458 | 0.710 |
Why?
|
| Middle Aged | 28 | 2025 | 26316 | 0.700 |
Why?
|
| Students, Pharmacy | 2 | 2019 | 63 | 0.670 |
Why?
|
| Cholinesterase Inhibitors | 3 | 2024 | 100 | 0.660 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 120 | 0.650 |
Why?
|
| Weight Gain | 3 | 2024 | 401 | 0.650 |
Why?
|
| Hepatic Encephalopathy | 1 | 2020 | 75 | 0.650 |
Why?
|
| Benchmarking | 1 | 2020 | 133 | 0.640 |
Why?
|
| Cancer Survivors | 2 | 2018 | 203 | 0.620 |
Why?
|
| Estrogen Antagonists | 1 | 2018 | 103 | 0.610 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 220 | 0.600 |
Why?
|
| Buprenorphine | 3 | 2025 | 95 | 0.580 |
Why?
|
| Hospitalization | 3 | 2020 | 1751 | 0.570 |
Why?
|
| Health Care Costs | 1 | 2020 | 369 | 0.560 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 314 | 0.560 |
Why?
|
| Cross-Sectional Studies | 15 | 2025 | 3406 | 0.540 |
Why?
|
| Patient Readmission | 1 | 2020 | 375 | 0.530 |
Why?
|
| Drug Combinations | 4 | 2020 | 267 | 0.520 |
Why?
|
| Arabs | 1 | 2015 | 29 | 0.510 |
Why?
|
| Schizophrenic Psychology | 1 | 2016 | 81 | 0.510 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2015 | 34 | 0.510 |
Why?
|
| Nicotinic Agonists | 1 | 2015 | 44 | 0.500 |
Why?
|
| Opioid-Related Disorders | 3 | 2025 | 261 | 0.500 |
Why?
|
| Tobacco Use Disorder | 1 | 2016 | 88 | 0.490 |
Why?
|
| Tobacco Products | 1 | 2015 | 61 | 0.490 |
Why?
|
| Universities | 3 | 2013 | 127 | 0.490 |
Why?
|
| Suicide, Attempted | 1 | 2016 | 133 | 0.480 |
Why?
|
| Adult | 28 | 2025 | 29303 | 0.470 |
Why?
|
| Primary Health Care | 1 | 2021 | 771 | 0.470 |
Why?
|
| Schizophrenia | 1 | 2016 | 300 | 0.430 |
Why?
|
| Telephone | 3 | 2019 | 110 | 0.420 |
Why?
|
| Pharmacists | 3 | 2020 | 84 | 0.410 |
Why?
|
| Health Behavior | 1 | 2015 | 383 | 0.410 |
Why?
|
| Social Perception | 1 | 2013 | 57 | 0.400 |
Why?
|
| Medicaid | 3 | 2024 | 243 | 0.400 |
Why?
|
| Risk-Taking | 2 | 2012 | 92 | 0.390 |
Why?
|
| Young Adult | 13 | 2025 | 8939 | 0.380 |
Why?
|
| Nicotine | 1 | 2013 | 141 | 0.380 |
Why?
|
| Insurance, Pharmaceutical Services | 2 | 2016 | 10 | 0.370 |
Why?
|
| Opiate Substitution Treatment | 3 | 2025 | 25 | 0.340 |
Why?
|
| Social Class | 2 | 2024 | 190 | 0.330 |
Why?
|
| Physicians | 4 | 2019 | 583 | 0.320 |
Why?
|
| Disease Management | 1 | 2012 | 522 | 0.300 |
Why?
|
| Patient Compliance | 2 | 2015 | 469 | 0.300 |
Why?
|
| Hydrocodone | 2 | 2019 | 35 | 0.290 |
Why?
|
| Blood Glucose | 4 | 2024 | 1131 | 0.290 |
Why?
|
| Adolescent | 15 | 2024 | 19269 | 0.290 |
Why?
|
| Interrupted Time Series Analysis | 2 | 2024 | 24 | 0.290 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2020 | 254 | 0.290 |
Why?
|
| Body Mass Index | 6 | 2024 | 1553 | 0.270 |
Why?
|
| Alzheimer Disease | 2 | 2024 | 786 | 0.270 |
Why?
|
| Proportional Hazards Models | 3 | 2020 | 1306 | 0.270 |
Why?
|
| Analgesics, Opioid | 3 | 2024 | 408 | 0.260 |
Why?
|
| Polypharmacy | 1 | 2005 | 40 | 0.250 |
Why?
|
| Health Services Accessibility | 2 | 2025 | 603 | 0.250 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 5086 | 0.240 |
Why?
|
| Risk Factors | 8 | 2024 | 10107 | 0.240 |
Why?
|
| Health Maintenance Organizations | 1 | 2004 | 22 | 0.240 |
Why?
|
| Aromatase Inhibitors | 3 | 2020 | 76 | 0.230 |
Why?
|
| Narcotic Antagonists | 1 | 2025 | 107 | 0.230 |
Why?
|
| Dabigatran | 1 | 2024 | 27 | 0.230 |
Why?
|
| Thalidomide | 1 | 2024 | 36 | 0.230 |
Why?
|
| Longitudinal Studies | 2 | 2025 | 1331 | 0.230 |
Why?
|
| Delirium | 1 | 2024 | 52 | 0.220 |
Why?
|
| Ambulatory Care | 2 | 2020 | 378 | 0.220 |
Why?
|
| Confidence Intervals | 3 | 2013 | 279 | 0.220 |
Why?
|
| Hypnotics and Sedatives | 1 | 2024 | 135 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 1124 | 0.210 |
Why?
|
| Hypolipidemic Agents | 1 | 2004 | 177 | 0.210 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2022 | 10 | 0.200 |
Why?
|
| Antidepressive Agents | 1 | 2025 | 290 | 0.200 |
Why?
|
| Databases, Factual | 2 | 2024 | 1176 | 0.200 |
Why?
|
| Multiple Myeloma | 1 | 2024 | 170 | 0.200 |
Why?
|
| Health Status Disparities | 1 | 2024 | 226 | 0.200 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2022 | 59 | 0.190 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2023 | 527 | 0.190 |
Why?
|
| Healthcare Disparities | 2 | 2025 | 426 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2023 | 1012 | 0.190 |
Why?
|
| Cognition Disorders | 1 | 2005 | 556 | 0.190 |
Why?
|
| Pharmacies | 1 | 2021 | 13 | 0.190 |
Why?
|
| Hypertriglyceridemia | 1 | 2022 | 102 | 0.190 |
Why?
|
| Qualitative Research | 1 | 2024 | 531 | 0.180 |
Why?
|
| Pharmacy | 1 | 2021 | 13 | 0.180 |
Why?
|
| Surveys and Questionnaires | 6 | 2023 | 3704 | 0.180 |
Why?
|
| Health Surveys | 2 | 2012 | 243 | 0.180 |
Why?
|
| HIV Infections | 3 | 2023 | 1869 | 0.180 |
Why?
|
| Comorbidity | 2 | 2016 | 1505 | 0.180 |
Why?
|
| Age Factors | 3 | 2025 | 2815 | 0.180 |
Why?
|
| Tamoxifen | 2 | 2020 | 363 | 0.180 |
Why?
|
| Diabetes Complications | 1 | 2022 | 196 | 0.180 |
Why?
|
| Odds Ratio | 3 | 2013 | 1245 | 0.180 |
Why?
|
| Controlled Substances | 2 | 2019 | 12 | 0.180 |
Why?
|
| Metformin | 1 | 2022 | 147 | 0.180 |
Why?
|
| Breast Neoplasms, Male | 1 | 2020 | 15 | 0.180 |
Why?
|
| Neomycin | 1 | 2020 | 37 | 0.170 |
Why?
|
| Lactulose | 1 | 2020 | 39 | 0.170 |
Why?
|
| Sex Factors | 2 | 2019 | 1266 | 0.170 |
Why?
|
| Sexual Behavior | 2 | 2013 | 247 | 0.170 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2022 | 839 | 0.170 |
Why?
|
| Gastrointestinal Agents | 1 | 2020 | 60 | 0.170 |
Why?
|
| Acute Pain | 1 | 2019 | 21 | 0.160 |
Why?
|
| Military Personnel | 2 | 2013 | 211 | 0.160 |
Why?
|
| Forecasting | 1 | 2021 | 356 | 0.160 |
Why?
|
| Psychological Theory | 2 | 2016 | 35 | 0.160 |
Why?
|
| Substance-Related Disorders | 1 | 2023 | 458 | 0.160 |
Why?
|
| Metabolic Syndrome | 1 | 2022 | 330 | 0.160 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 170 | 0.160 |
Why?
|
| Cholesterol, LDL | 1 | 2022 | 560 | 0.150 |
Why?
|
| Intention | 2 | 2016 | 91 | 0.150 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2021 | 216 | 0.150 |
Why?
|
| Quinolines | 1 | 2019 | 95 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2022 | 419 | 0.150 |
Why?
|
| Health Services | 1 | 2018 | 71 | 0.150 |
Why?
|
| Standard of Care | 1 | 2018 | 129 | 0.150 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 1415 | 0.150 |
Why?
|
| Prospective Studies | 2 | 2019 | 6084 | 0.140 |
Why?
|
| Health Care Surveys | 2 | 2019 | 285 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2019 | 448 | 0.140 |
Why?
|
| Chronic Pain | 1 | 2019 | 129 | 0.140 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 280 | 0.140 |
Why?
|
| Chronic Disease | 1 | 2021 | 1180 | 0.140 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 180 | 0.140 |
Why?
|
| Insulin Resistance | 1 | 2022 | 644 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 1236 | 0.140 |
Why?
|
| Perception | 2 | 2022 | 220 | 0.140 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 175 | 0.140 |
Why?
|
| Middle East | 2 | 2016 | 34 | 0.140 |
Why?
|
| Smoking Prevention | 1 | 2016 | 37 | 0.130 |
Why?
|
| Depression | 1 | 2025 | 1243 | 0.130 |
Why?
|
| Mental Disorders | 1 | 2023 | 822 | 0.130 |
Why?
|
| Recurrence | 1 | 2020 | 1425 | 0.130 |
Why?
|
| Health Planning Guidelines | 1 | 2016 | 32 | 0.130 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 25 | 0.130 |
Why?
|
| Self-Injurious Behavior | 1 | 2016 | 64 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2020 | 1396 | 0.130 |
Why?
|
| Linear Models | 1 | 2017 | 670 | 0.120 |
Why?
|
| Receptor, ErbB-2 | 3 | 2023 | 504 | 0.120 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 428 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2018 | 4727 | 0.120 |
Why?
|
| Cholinergic Antagonists | 2 | 2024 | 51 | 0.110 |
Why?
|
| Blood Pressure | 1 | 2019 | 1329 | 0.110 |
Why?
|
| Risk | 1 | 2015 | 748 | 0.110 |
Why?
|
| Propylene Glycol | 1 | 2013 | 9 | 0.110 |
Why?
|
| Social Values | 1 | 2013 | 47 | 0.100 |
Why?
|
| Child | 8 | 2024 | 24417 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2023 | 55 | 0.100 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2013 | 57 | 0.100 |
Why?
|
| Pakistan | 1 | 2012 | 77 | 0.100 |
Why?
|
| Jordan | 1 | 2012 | 8 | 0.100 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2013 | 93 | 0.100 |
Why?
|
| India | 1 | 2012 | 218 | 0.100 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 352 | 0.100 |
Why?
|
| Focus Groups | 1 | 2013 | 202 | 0.100 |
Why?
|
| Sunlight | 1 | 2011 | 23 | 0.100 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 595 | 0.090 |
Why?
|
| Overweight | 1 | 2014 | 359 | 0.090 |
Why?
|
| Data Collection | 1 | 2013 | 384 | 0.090 |
Why?
|
| Health Personnel | 1 | 2016 | 504 | 0.090 |
Why?
|
| Self Report | 1 | 2014 | 517 | 0.090 |
Why?
|
| HIV Seropositivity | 1 | 2011 | 117 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 71 | 0.090 |
Why?
|
| Cholesterol | 2 | 2023 | 532 | 0.090 |
Why?
|
| Vitamin D | 1 | 2011 | 159 | 0.080 |
Why?
|
| Public Health | 1 | 2012 | 260 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2022 | 12240 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 2411 | 0.080 |
Why?
|
| Drug and Narcotic Control | 2 | 2019 | 18 | 0.080 |
Why?
|
| Incidence | 1 | 2015 | 3074 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 355 | 0.070 |
Why?
|
| Socioeconomic Factors | 2 | 2025 | 869 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2023 | 3256 | 0.060 |
Why?
|
| New England | 1 | 2004 | 12 | 0.060 |
Why?
|
| Child Psychiatry | 1 | 2024 | 16 | 0.060 |
Why?
|
| Drug Utilization | 1 | 2005 | 161 | 0.060 |
Why?
|
| Aripiprazole | 1 | 2024 | 20 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 726 | 0.060 |
Why?
|
| Regression Analysis | 1 | 2005 | 773 | 0.060 |
Why?
|
| Treatment Refusal | 1 | 2004 | 77 | 0.060 |
Why?
|
| Patient Acuity | 1 | 2023 | 64 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2005 | 271 | 0.050 |
Why?
|
| Drug Monitoring | 1 | 2024 | 166 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2024 | 371 | 0.050 |
Why?
|
| Mortality | 1 | 2004 | 229 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2023 | 38 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2024 | 178 | 0.050 |
Why?
|
| Health Status | 1 | 2024 | 376 | 0.050 |
Why?
|
| Managed Care Programs | 1 | 2022 | 61 | 0.050 |
Why?
|
| Obesity, Abdominal | 1 | 2022 | 37 | 0.050 |
Why?
|
| Lipoproteins, HDL | 1 | 2022 | 97 | 0.050 |
Why?
|
| Nigeria | 2 | 2013 | 79 | 0.050 |
Why?
|
| Mexico | 1 | 2022 | 180 | 0.050 |
Why?
|
| Postmenopause | 1 | 2022 | 125 | 0.050 |
Why?
|
| Sexual Partners | 2 | 2013 | 85 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 250 | 0.050 |
Why?
|
| Neoplasms | 1 | 2016 | 2781 | 0.050 |
Why?
|
| Research | 1 | 2023 | 263 | 0.050 |
Why?
|
| Health Expenditures | 1 | 2022 | 103 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2004 | 638 | 0.040 |
Why?
|
| Attitude of Health Personnel | 2 | 2016 | 657 | 0.040 |
Why?
|
| Mastectomy | 1 | 2020 | 64 | 0.040 |
Why?
|
| Aftercare | 1 | 2021 | 147 | 0.040 |
Why?
|
| Lipids | 1 | 2022 | 513 | 0.040 |
Why?
|
| Breast | 1 | 2020 | 214 | 0.040 |
Why?
|
| Cognition | 1 | 2023 | 737 | 0.040 |
Why?
|
| Analgesics | 1 | 2019 | 134 | 0.040 |
Why?
|
| Survival Rate | 1 | 2023 | 2016 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 760 | 0.040 |
Why?
|
| United States Government Agencies | 1 | 2016 | 5 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2020 | 792 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 1217 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2020 | 872 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1101 | 0.030 |
Why?
|
| Models, Psychological | 1 | 2016 | 138 | 0.030 |
Why?
|
| Reimbursement, Incentive | 1 | 2016 | 47 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2015 | 129 | 0.030 |
Why?
|
| Mammography | 1 | 2015 | 113 | 0.030 |
Why?
|
| SEER Program | 1 | 2015 | 194 | 0.030 |
Why?
|
| Saudi Arabia | 1 | 2013 | 39 | 0.030 |
Why?
|
| Cisplatin | 1 | 2015 | 243 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2020 | 722 | 0.030 |
Why?
|
| Methotrexate | 1 | 2015 | 352 | 0.030 |
Why?
|
| Communication | 1 | 2016 | 516 | 0.020 |
Why?
|
| Registries | 1 | 2018 | 1407 | 0.020 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 93 | 0.020 |
Why?
|
| Condoms | 1 | 2010 | 48 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2010 | 192 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2024 | 14021 | 0.020 |
Why?
|
| Prevalence | 1 | 2011 | 2422 | 0.010 |
Why?
|
| Heart Failure | 1 | 2016 | 2156 | 0.010 |
Why?
|